摘要
癌症治疗仍然是一个挑战,因为目前使用的化疗药物的几个限制,如其不良的药代动力学,不利的化学性质,以及无法区分健康和疾病的组织。纳米技术为克服这些限制提供了有力的工具。(2)改善水溶性差的药物的理化性质,如紫杉醇;(3)选择性地将化疗药物运送到肿瘤病灶,从而减少非靶点的毒性,并促进细胞内的内化。为了实现这一目的,已经制定了几项战略,这些战略是基于在当地和系统地发生的因肿瘤发生而发生的生物和物理变化而制定的。在这里,我们将讨论炎症在肿瘤发展的不同阶段中的作用,以及利用纳米粒子开发炎症途径的策略,以便选择性地将肿瘤相关的微环境作为治疗和诊断的目标。
关键词: 纳米医学,仿生纳米粒子,炎症,活性靶向,癌症,热疗,发炎血管。
Current Medicinal Chemistry
Title:Inflammation and Cancer: In Medio Stat Nano
Volume: 25 Issue: 34
关键词: 纳米医学,仿生纳米粒子,炎症,活性靶向,癌症,热疗,发炎血管。
摘要: Cancer treatment still remains a challenge due to the several limitations of currently used chemotherapeutics, such as their poor pharmacokinetics, unfavorable chemical properties, as well as inability to discriminate between healthy and diseased tissue. Nanotechnology offered potent tools to overcome these limitations. Drug encapsulation within a delivery system permitted i) to protect the payload from enzymatic degradation/ inactivation in the blood stream, ii) to improve the physicochemical properties of poorly water-soluble drugs, like paclitaxel, and iii) to selectively deliver chemotherapeutics to the cancer lesions, thus reducing the off-target toxicity, and promoting the intracellular internalization. To accomplish this purpose, several strategies have been developed, based on biological and physical changes happening locally and systemically as a consequence of tumorigenesis. Here, we will discuss the role of inflammation in the different steps of tumor development and the strategies based on the use of nanoparticles that exploit the inflammatory pathways in order to selectively target the tumor-associated microenvironment for therapeutic and diagnostic purposes.
Export Options
About this article
Cite this article as:
Inflammation and Cancer: In Medio Stat Nano, Current Medicinal Chemistry 2018; 25 (34) . https://dx.doi.org/10.2174/0929867324666170920160030
DOI https://dx.doi.org/10.2174/0929867324666170920160030 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Signal Transduction by IL-2 and its Receptors as Target in Treatment of Rheumatoid Arthritis
Current Drug Targets - Immune, Endocrine & Metabolic Disorders FDG-PET/CT for Systemic Infections
Current Molecular Imaging (Discontinued) Radiological Diagnosis of Renal Thrombosis in Children
Current Pediatric Reviews Vascular Effects of Phytoestrogens and Alternative Menopausal Hormone Therapy in Cardiovascular Disease
Mini-Reviews in Medicinal Chemistry Meet Our Editorial Board Member:
Current Rheumatology Reviews Drug Induced Cutaneous Manifestations due to Treatment of Gastrointestinal Disorders
Current Drug Metabolism Soluble Adhesion Molecules in the Pathogenesis of Rheumatoid Arthritis
Current Pharmaceutical Design A More Accurate Approach to Molecular Genetics Analysis in Vascular Disease
Cardiovascular & Hematological Disorders-Drug Targets Non-coding RNAs and Hypertension–Unveiling Unexpected Mechanisms of Hypertension by the Dark Matter of the Genome
Current Hypertension Reviews Catastrophic Antiphospholipid Syndrome - 20 Years Later
Current Rheumatology Reviews Established Treatments of Psoriasis
Current Drug Targets - Inflammation & Allergy Correlation Analysis of Capillary APOE, VEGF and eNOS Expression in Alzheimer Brains
Current Alzheimer Research The Phage Display Technique: Advantages and Recent Patents
Recent Patents on DNA & Gene Sequences Update on the Rheumatologic Manifestations of Malignancy
Current Cancer Therapy Reviews Oxidative Stress Modulation Through Habitual Physical Activity
Current Pharmaceutical Design Oxidative Brain Damage by Peroxynitrite in Bacterial Meningitis: A Target for Adjunctive Therapy?
Current Medicinal Chemistry - Central Nervous System Agents MMP Inhibitors in Cardiac Diseases: An Update
Recent Patents on Cardiovascular Drug Discovery Harnessing CD36 to Rein in Inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets Is Bilirubin a Marker of Vascular Disease and/or Cancer and is it a Potential Therapeutic Target?
Current Pharmaceutical Design Role of Vasa Vasorum in Arterial Disease: A Re-emerging Factor
Current Cardiology Reviews